These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 16554944)

  • 1. Disease modifying trials in Alzheimer disease: methodological and statistical issues.
    Andrieu S; Rascol O; Lang T; Grandjean H; Vellas B
    J Nutr Health Aging; 2006; 10(2):116-7. PubMed ID: 16554944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes for disease modifying trials.
    Wilcok G
    J Nutr Health Aging; 2007; 11(4):318-9. PubMed ID: 17653489
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues.
    Sankoh AJ; D'Agostino RB; Huque MF
    Stat Med; 2003 Oct; 22(20):3133-50. PubMed ID: 14518019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining and labeling disease-modifying treatments for Alzheimer's disease.
    Cummings JL
    Alzheimers Dement; 2009 Sep; 5(5):406-18. PubMed ID: 19751920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs.
    Scheltens P; Barkhof F
    J Nutr Health Aging; 2006; 10(2):123-8; discussion 129-30. PubMed ID: 16554946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using disease progression models as a tool to detect drug effect.
    Mould DR; Denman NG; Duffull S
    Clin Pharmacol Ther; 2007 Jul; 82(1):81-6. PubMed ID: 17507925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis.
    Ploeger BA; Holford NH
    Pharm Stat; 2009; 8(3):225-38. PubMed ID: 19025967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial treatment length optimization with an emphasis on disease progression studies.
    Hennig S; Nyberg J; Hooker AC; Karlsson MO
    J Clin Pharmacol; 2009 Mar; 49(3):323-35. PubMed ID: 19246730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease?
    Gauthier S; Poirier J
    Alzheimers Dement; 2009 Mar; 5(2):147-8. PubMed ID: 19328447
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methodological issues in clinical trials of drug and behavior therapies.
    Holroyd KA; Powers SW; Andrasik F
    Headache; 2005 May; 45(5):487-92. PubMed ID: 15953265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An introduction to statistical concepts for the analysis of EEG data and the planning of pharmaco-EEG trials.
    Schlattmann P
    Methods Find Exp Clin Pharmacol; 2002; 24 Suppl C():1-6. PubMed ID: 12575482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A note on special articles on adaptive clinical trial designs.
    Chow SC
    J Biopharm Stat; 2010 Nov; 20(6):1088-9. PubMed ID: 21058103
    [No Abstract]   [Full Text] [Related]  

  • 16. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scales as outcome measures for Alzheimer's disease.
    Black R; Greenberg B; Ryan JM; Posner H; Seeburger J; Amatniek J; Resnick M; Mohs R; Miller DS; Saumier D; Carrillo MC; Stern Y
    Alzheimers Dement; 2009 Jul; 5(4):324-39. PubMed ID: 19560103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of clinical trials of gene therapy in Parkinson disease.
    Lewis TB; Standaert DG
    Exp Neurol; 2008 Jan; 209(1):41-7. PubMed ID: 17920590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs.
    Santen G; Horrigan J; Danhof M; Della Pasqua O
    Clin Pharmacol Ther; 2009 Sep; 86(3):255-62. PubMed ID: 19675543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.